Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.

Alessandrini F, Menotti L, Avitabile E, Appolloni I, Ceresa D, Marubbi D, Campadelli-Fiume G, Malatesta P.

Oncogene. 2019 Jun;38(23):4467-4479. doi: 10.1038/s41388-019-0737-2. Epub 2019 Feb 12.

PMID:
30755732
2.

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.

Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G.

Viruses. 2018 Jun 30;10(7). pii: E352. doi: 10.3390/v10070352.

3.

How can nanotechnology help the fight against breast cancer?

Avitabile E, Bedognetti D, Ciofani G, Bianco A, Delogu LG.

Nanoscale. 2018 Jul 5;10(25):11719-11731. doi: 10.1039/c8nr02796j. Review.

PMID:
29917035
4.

Retargeting Strategies for Oncolytic Herpes Simplex Viruses.

Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V.

Viruses. 2016 Feb 26;8(3):63. doi: 10.3390/v8030063. Review.

5.

Sex-associated differences in the modulation of vascular risk in patients with asymptomatic carotid stenosis.

Buratti L, Balestrini S, Avitabile E, Altamura C, Vernieri F, Viticchi G, Falsetti L, Provinciali L, Silvestrini M.

J Cereb Blood Flow Metab. 2015 Mar 31;35(4):684-8. doi: 10.1038/jcbfm.2014.248.

6.

Cognitive deterioration in bilateral asymptomatic severe carotid stenosis.

Buratti L, Balucani C, Viticchi G, Falsetti L, Altamura C, Avitabile E, Provinciali L, Vernieri F, Silvestrini M.

Stroke. 2014 Jul;45(7):2072-7. doi: 10.1161/STROKEAHA.114.005645. Epub 2014 Jun 5.

PMID:
24903984
7.

Viral and cellular contributions to herpes simplex virus entry into the cell.

Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T.

Curr Opin Virol. 2012 Feb;2(1):28-36. doi: 10.1016/j.coviro.2011.12.001. Epub 2012 Jan 4. Review.

PMID:
22440963
8.

Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD.

Avitabile E, Forghieri C, Campadelli-Fiume G.

J Virol. 2009 Oct;83(20):10752-60. doi: 10.1128/JVI.01287-09. Epub 2009 Aug 5.

9.
10.

The multipartite system that mediates entry of herpes simplex virus into the cell.

Campadelli-Fiume G, Amasio M, Avitabile E, Cerretani A, Forghieri C, Gianni T, Menotti L.

Rev Med Virol. 2007 Sep-Oct;17(5):313-26. Review.

PMID:
17573668
12.

Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis: role of nuclear factor kappaB.

Medici MA, Sciortino MT, Perri D, Amici C, Avitabile E, Ciotti M, Balestrieri E, De Smaele E, Franzoso G, Mastino A.

J Biol Chem. 2003 Sep 19;278(38):36059-67. Epub 2003 Jul 4.

14.

Retinoids and cancer: antitumoral effects of ATRA, 9-cis RA and the new retinoid IIF on the HL-60 leukemic cell line.

Orlandi M, Mantovani B, Ammar K, Avitabile E, Dal Monte P, Bartolini G.

Med Princ Pract. 2003 Jul-Sep;12(3):164-9.

16.

Novel, soluble isoform of the herpes simplex virus (HSV) receptor nectin1 (or PRR1-HIgR-HveC) modulates positively and negatively susceptibility to HSV infection.

Lopez M, Cocchi F, Avitabile E, Leclerc A, Adelaide J, Campadelli-Fiume G, Dubreuil P.

J Virol. 2001 Jun;75(12):5684-91.

17.
18.

The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gD.

Menotti L, Lopez M, Avitabile E, Stefan A, Cocchi F, Adelaide J, Lecocq E, Dubreuil P, Campadelli-Fiume G.

Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4867-72.

19.
21.
22.

Identification of an 85 kDa phosphoprotein as an immunodominant protein specific for human herpesvirus 7-infected cells.

Foà-Tomasi L, Fiorilli MP, Avitabile E, Campadelli-Fiume G.

J Gen Virol. 1996 Mar;77 ( Pt 3):511-8.

PMID:
8601789
23.

Redistribution of microtubules and Golgi apparatus in herpes simplex virus-infected cells and their role in viral exocytosis.

Avitabile E, Di Gaeta S, Torrisi MR, Ward PL, Roizman B, Campadelli-Fiume G.

J Virol. 1995 Dec;69(12):7472-82.

24.

Selection of a monoclonal antibody specific for variant B human herpesvirus 6-infected mononuclear cells.

Foà-Tomasi L, Avitabile E, Campadelli-Fiume G.

J Virol Methods. 1995 Feb;51(2-3):289-96.

PMID:
7738149
25.

Localization and putative function of the UL20 membrane protein in cells infected with herpes simplex virus 1.

Ward PL, Campadelli-Fiume G, Avitabile E, Roizman B.

J Virol. 1994 Nov;68(11):7406-17.

27.
28.

Herpes simplex virus (HSV) glycoprotein H is partially processed in a cell line that expresses the glycoprotein and fully processed in cells infected with deletion or ts mutants in the known HSV glycoproteins.

Foà-Tomasi L, Avitabile E, Boscaro A, Brandimarti R, Gualandri R, Manservigi R, Dall'Olio F, Serafini-Cessi F, Fiume GC.

Virology. 1991 Feb;180(2):474-82.

PMID:
1846486
29.
30.

Glycoprotein C-dependent attachment of herpes simplex virus to susceptible cells leading to productive infection.

Campadelli-Fiume G, Stirpe D, Boscaro A, Avitabile E, Foá-Tomasi L, Barker D, Roizman B.

Virology. 1990 Sep;178(1):213-22.

PMID:
2167550
31.

Herpes simplex virus glycoprotein D is sufficient to induce spontaneous pH-independent fusion in a cell line that constitutively expresses the glycoprotein.

Campadelli-Fiume G, Avitabile E, Fini S, Stirpe D, Arsenakis M, Roizman B.

Virology. 1988 Oct;166(2):598-602.

PMID:
3051654
32.
33.

Comparative biochemistry of the ubiquinol-cytochrome c oxidoreductase (EC 1.10.2.2) isolated from different heart mitochondria.

Degli Esposti M, Avitabile E, Barilli M, Schiavo G, Montecucco C, Lenaz G.

Comp Biochem Physiol B. 1986;85(3):543-52.

PMID:
3024904

Supplemental Content

Loading ...
Support Center